| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Division of Infectious Diseases, Department of Medicine, University of Maryland School of Medicine, HSF II, 20 Penn Street, Baltimore, MD 21201, USA
2 Department of Veterans Affairs, Baltimore, MD 21201, USA
Correspondence
Michael S. Donnenberg
mdonnenb{at}umaryland.edu
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
; Litwin et al., 2005). Thus, UTIs represent a significant medical-economic burden to the healthcare system. Most UTIs develop by the ascending route of infection, by which periurethral micro-organisms enter through the urethra and progress upward into the bladder lumen. The bacteria may ascend further via the ureters into the kidneys and even breach the kidney parenchyma to enter the lymphatic system or the bloodstream. Therefore, the manifestations of UTI can range from asymptomatic bacteriuria to urethritis, cystitis, pyelonephritis, bacteraemia and septic shock. E. coli is responsible for 70–90 % of the seven million cases of acute cystitis and 250 000 cases of pyelonephritis reported annually in the USA.
Certain O : K : H serotypes and virulence factors occur more frequently in urinary isolates than in faecal isolates, suggesting that uropathogenic E. coli (UPEC) strains are different from commensal E. coli. Recent evidence suggests that similar factors and clones are found among other extraintestinal E. coli infections, indicating that ExPEC are indistinguishable from UPEC (Johnson & Russo, 2002). A limited number of virulence factors, including adhesins, iron-uptake systems, toxins and capsules, have been implicated as important traits allowing these strains to cause disease. Nonetheless, no single virulence factor or set of factors can uniquely identify UPEC.
Our laboratory studies the ExPEC strain CFT073, a highly virulent strain isolated from the blood of a woman with acute pyelonephritis (Mobley et al., 1990). This strain is considered to be a prototype of the O6 serogroup and its virulence has been reproduced in the well-established CBA mouse model of ascending UTI (Mobley et al., 1990). Potential urovirulence factors that have been identified for CFT073 and other ExPEC strains include type l fimbriae, secreted autotransporter toxin, cytotoxic necrotizing factor, iron-transporting outer-membrane protein TonB, osmoprotectant ProP, transcriptional regulator RfaH and DegS (Connell et al., 1996; Bahrani-Mougeot et al., 2002; Guyer et al., 2002; Rippere-Lampe et al., 2001; Torres et al., 2001; Culham et al., 1998; Nagy et al., 2002; Redford et al., 2003). Of these factors, only type 1 fimbriae, TonB, RfaH and DegS have been proven to be required for pathogenesis by inactivation of genes required for their expression and complementation to restore the virulence defect. Recently, the genomic sequence of CFT073 was reported and revealed additional factors that may contribute to the pathogenesis of UTIs, such as additional fimbriae, several autotransporters and a type I RTX-like secretion system (Welch et al., 2002).
Previously, we used signature-tagged mutagenesis (STM) to identify genes that are essential for the survival of CFT073 within the murine urinary tract (Bahrani-Mougeot et al., 2002). Among the genetic loci implicated by this study was the phoU gene. The phoU gene is the last cistron in the pstSCAB–phoU operon, which encodes a phosphate-specific transport system (Pst) that actively transports inorganic phosphate (Pi) into E. coli cells (Surin et al., 1985). The Pst system is part of the Pho regulon and is induced under Pi starvation conditions (Wanner, 1996). PstS is the periplasmic Pi-binding protein; PstA and PstC are integral membrane proteins that mediate the translocation of Pi through the inner membrane; and PstB is an ATPase that energizes the transport. PhoU is a peripheral membrane protein and its role in phosphate transport is controversial (Surin et al., 1985; Nakata et al., 1984). The phoU35 allele, which results in the replacement of alanine-147 with glutamate, has no effect on phosphate uptake. However, a phoU deletion mutant has been reported to have reduced phosphate uptake (Muda et al., 1992). In contrast, several phoU alleles, including two missense mutations and an insertion, have been reported to lead to increased intracellular accumulation of polyphosphate (Morohoshi et al., 2002). Yet another phoU deletion mutant was reported to be unaffected in phosphate transport (Steed & Wanner, 1993). Interestingly, this last mutant had a severe growth defect and it was suggested that spontaneous compensatory mutations in the pst operon, phoB or phoR may have alleviated this defect.
The Pst system also negatively regulates the Pho regulon, a set of genes and operons that are regulated by the concentration of Pi in the medium. Mutations in the pst genes, as well as phoU, lead to constitutive expression of all Pho genes, such as phoA, encoding alkaline phosphatase. However, PhoU does not appear to act directly as a repressor, since overexpression of PhoU under low phosphate does not lead to decreased alkaline phosphatase expression (Muda et al., 1992). The Pho regulon including the pstSCAB genes is co-regulated by the PhoR–PhoB two-component regulatory system. Under Pi starvation conditions the sensor kinase PhoR phosphorylates PhoB, and phosphorylated PhoB in turn activates transcription of the Pho regulon genes. It has been suggested that PhoU interacts with components of the PstSCAB transporter under conditions of phosphate excess to form a repressor complex and that this complex acts a negative regulator (Steed & Wanner, 1993). However, direct evidence of such interactions is lacking.
In this study, we further characterize the phoU mutant of CFT073 in an effort to determine its effect on the Pho regulon, on growth and on colonization in the murine model of ascending UTI.
|
METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
. E. coli strain CFT073 was isolated from the blood of an otherwise healthy woman admitted to the University of Maryland Medical Center with the clinical syndrome of acute pyelonephritis. CFT073 is highly virulent in the murine urinary tract and its genome has been sequenced (Welch et al., 2002). Bacteria were stored at –70 °C in 50 % Luria–Bertani (LB) broth and 50 % glycerol and were routinely grown at 37 °C in LB broth or on Luria agar supplemented with appropriate antibiotics. Antibiotics were used at the following concentrations: ampicillin, 50 µg ml–1; kanamycin, 50 µg ml–1; nalidixic acid, 50 µg ml–1; and rifampicin, 50 µg ml–1.
|
). The enzymes and chemicals used for DNA manipulation were purchased from Invitrogen and New England Biolabs. DNA fragments used in the cloning procedures and PCR products were isolated from agarose gels with the Qiaquick gel extraction kit (Qiagen). Plasmid DNA from E. coli was isolated and purified with a Wizard Plus minipreps DNA purification system (Promega) or a Qiagen plasmid midi kit. Plasmids were introduced into E. coli by electroporation or by chemical methods. Primers used in this study were synthesized at the University of Maryland School of Medicine.
Complementation of the phoU mutant.
The full-length coding region of phoU was amplified by PCR using primers Donne 904 (5'-CCC GAC TTC ACC AGT ATT CTC TGG TTA TGT CAG G-3') and Donne 905 (5'-CGG CAC TCG ACC CTA TCT CTA CCG GGC G-3'). The PCR product was then cloned into Zero Blunt TOPO vector (Invitrogen) as described by the manufacturer to yield plasmid pXLW28. The nucleotide sequence of the insert was confirmed by sequence analysis. Plasmid pXLW28 was then digested with EcoRI, yielding a fragment of approximately 1·2 kb containing the phoU gene. This fragment was gel-purified and ligated into pWKS30 to yield pXLW31.
SDS-PAGE and immunoblot analysis.
Whole-cell lysates were denatured by boiling for 5 min in SDS-PAGE sample buffer. Proteins were separated by SDS-PAGE and transferred to an Immobilon-P PVDF membrane using a semi-dry Multiphor II NovaBlot transfer apparatus (Amersham Pharmacia Biotech). After incubation overnight at 4 °C in blocking reagent (5 % dried skimmed milk in PBS and 0·1 % Tween 20), the membrane was probed with anti-PhoU serum (1 : 5000, kindly provided by J. P. M. Tommassen, Utrecht University, The Netherlands) and horseradish-peroxidase-conjugated anti-rabbit serum (Amersham Pharmacia Biotech) as the secondary antibody. The membranes were thoroughly washed and developed using the enhanced chemiluminescent detection kit (Amersham Pharmacia Biotech).
Alkaline phosphatase assay.
Alkaline phosphatase activities were measured as described by Brinkman & Beckwith (1975). Briefly, strains were grown overnight in LB broth as described above. The cultures were diluted and allowed to grow in minimal MOPS medium with excess phosphate (1·32 mM) or limiting phosphate (0·10 mM) to an OD600 of 0·5, centrifuged, washed, and resuspended in their original volume of MOPS. The cell density of each sample was confirmed by measuring the OD600. A volume of cells (100 µl) was added to AP buffer (1 M Tris pH 8·0) to a final volume of 0·9 ml, 100 µl 0·4 % p-nitrophenyl phosphate (Sigma) was added, and the reaction was started by incubation at 37 °C. Reactions were stopped by adding 120 µl stop solution (1 : 5 mix of 0·5 M EDTA and 1 M KH2PO4). The activity per cell was calculated in Miller units.
Growth in human urine.
Urine was collected from healthy women volunteers aged 20–40 who had no history of UTI or antibiotic use in the preceding 2 months. Each urine sample was immediately filter-sterilized and frozen at –80 °C for use within 2 weeks. For each experiment, a different pool of urine samples from three to five volunteers was used. The Institutional Review Board of the University of Maryland School of Medicine approved the study. The strain to be tested was grown overnight in LB medium with the appropriate antibiotics. The next day, bacterial cells were diluted into urine to achieve a starting OD600 of <0·05. During incubation at 37 °C with shaking, aliquots were removed at various time points and the bacterial titres determined by plating 10-fold serial dilutions in phosphate-buffered saline in duplicate on the appropriate medium.
Mouse experimental infections.
A CBA mouse model of ascending UTI was used as described by Mobley et al. (1990). Briefly, CBA mice were transurethrally challenged with 108 c.f.u. of bacteria per mouse. After 2 days, the mice were sacrificed and bacteria recovered from the urinary bladder, and kidneys were enumerated on plates containing appropriate antibiotics. For co-challenge infections, mice were inoculated with a mixture of 5x107 c.f.u. of the wild-type strain CFT073 (RifR) and 5x107 of the mutant (KanR) (total of 108 c.f.u. per inoculum), which had been grown separately overnight. In these experiments, both the wild-type and mutant strain contained the vector pWKS30 or the wild-type strain contained pWKS30 while the mutant contained the complementing plasmid pXLW31. After 48 h, urine was collected; bladder and kidneys were removed, weighed and homogenized; and dilutions were plated on selective media containing rifampicin or kanamycin using a spiral plater. After overnight growth, the viable counts were determined as c.f.u. per ml urine or c.f.u. per g tissue. As the lower limit of detection was 102 c.f.u., samples yielding no colonies were scored as having this value. A competitive index was calculated for each mutant as the geometric mean of the ratios of the mutant to the wild-type strains recovered from each sample site divided by the ratios of the mutant to the wild-type strains in the inoculum.
For statistical analysis, The Mann–Whitney test was used to compare the distributions of the number of c.f.u. per ml or per g in independent infection assays. A repeated measure analysis of variance with rank order data (STATA software) was used for statistical analysis of the co-challenge experimental data as previously described (Bahrani-Mougeot et al., 2002). P values of 
0·05 were considered significant.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
). During this previous analysis, mutant 3A-E4 was identified as a phoU mutant that was significantly out-competed by the wild-type strain in vivo, but able to grow as well as the wild-type in vitro. To further characterize this mutant, we determined by sequence analysis that the transposon inserted within the phoU gene at the 3' end, 50 bp upstream of the stop codon. Western blot analysis was performed to determine if PhoU expression was affected by the transposon insertion. As shown in Fig. 1, the PhoU protein was present in the wild-type strain but could not be detected in the mutant strain, indicating that the transposon disrupted the expression of PhoU. Transformation of mutant 3A-E4 with plasmid pXLW31 containing the phoU gene, including its ribosome-binding site, restored the expression of PhoU.
|
, the mutant had derepressed alkaline phosphate activity, especially under high-phosphate conditions, but this disregulation was corrected by the complementing plasmid. Restoration of alkaline phosphatase activity in the mutant to wild-type levels by pXLW31 indicates that the cloned phoU gene is functional. These data demonstrated in vitro trans complementation by the recombinant phoU gene, restoring PhoU expression and alkaline phosphatase activity to wild-type levels and verifying that these phenotypes were due to the phoU mutation.
|
). Thus, PhoU does not appear to be required for colonization of the murine urinary tract in experiments involving separate inoculation. However, this result does not exclude a subtle role for PhoU that cannot be detected under these conditions.
|
(a), the phoU mutant strain was recovered at significantly lower levels than wild-type CFT073 in the kidneys and urine when both strains contained the plasmid vector control pWKS30. Levels of colonization of the bladder by the phoU mutant tended to be lower than those of colonization by wild-type strain CFT073; however, the difference was not significant. Overall, the phoU mutant strain was out-competed by the wild-type strain in the bladder, kidneys and urine when considered together (P<0·001). When the phoU mutant strain was complemented with pXLW31, the ability to compete successfully with the wild-type was restored (Fig. 4b). The complemented strain was recovered from the urine, kidneys and bladder in numbers comparable to those of the wild-type strain. These results indicate that the ability to produce PhoU is critical to allow ExPEC strain CFT073 to compete for colonization of the murine urinary tract.
|
). However, sequencing of the pstSCAB and the phoBR genes of the phoU mutant revealed no mutation within these genes compared to the published sequence from the wild-type strain. To verify that inactivation of phoU did not affect growth of the mutant, we compared the growth of the wild-type parent CFT073 with the phoU mutant in LB broth. We detected no difference between the wild-type and mutant strains when grown separately in LB broth (not shown). Similarly, when the two strains, each containing a control plasmid, were inoculated together in LB, they grew at similar rates (Fig. 5a). Except for the 6 h time point, when the wild-type strain outcompeted the mutant, there were no significant differences in colony counts between the strains at any time point. When the wild-type containing the control plasmid and the mutant strain complemented with a plasmid containing the phoU gene were grown together in LB, there were no significant differences at any time point (Fig. 5b). This result suggests that the phoU mutation had only a subtle effect on the growth of CFT073 in laboratory media. Similar results were obtained when the wild-type and mutant strains were grown separately in human urine in vitro (data not shown). However, in competition growth experiments in human urine, the wild-type out-competed the phoU mutant during the entire growth period when both strains contained the control plasmid (Fig. 5c). The differences between the wild-type and mutant strains reached statistical significance at 4 and 6 h. This difference was reduced, but not eliminated, by complementation (Fig. 5d); none of these differences were statistically significant. These results suggest that mutation of phoU results in a competitive disadvantage for growth that is most apparent in human urine and the murine urinary tract.
|
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
). In addition, environmental signals such as temperature, nutrient availability, pH, osmolarity and starvation for phosphate have all been shown to influence bacterial virulence gene expression. Previously, we identified a phoU mutant of ExPEC strain CFT073 and demonstrated that this mutant was attenuated for survival in the murine urinary tract. This finding suggested that the PhoU protein might serve as a urovirulence factor by indirectly affecting the expression of virulence-related genes, leading to attenuation. In this report, we demonstrate that PhoU enhances the ability of prototype ExPEC strain CFT073 to survive and to colonize the murine urinary tract. Thus PhoU joins a shortlist of confirmed urovirulence factors. The role of PhoU in CFT073 colonization of the urinary tract was assessed by comparing the phoU mutant with wild-type strain CFT073 in the murine model of ascending UTI. In single-infection assays, quantitative cultures of urine, bladder and kidney revealed no difference between the wild-type strain CFT073 and the phoU mutant strain in the ability to colonize the mouse urinary tract. However, in competitive colonization experiments, the phoU mutant strain was significantly out-competed by the wild-type strain in the kidneys and urine and recovered in lower amount in the bladder. Importantly, reintroduction of the phoU gene into the mutant abolished this difference, proving that the PhoU itself is responsible for this competitive advantage.
Other members of the pst operon have been suggested to be important in the virulence of various pathogens. Recently, Burall et al. (2004) identified attenuated mutants with insertions in the pstS and pstC genes by STM of uropathogenic Proteus mirabilis. A mutation in pstC rendered a strain of E. coli that causes bacteraemia in pigs both avirulent and serum sensitive (Daigle et al., 1995). The pstS gene of Salmonella enterica serovar Typhimurium was identified as a macrophage-inducible gene and a mutation in pstS was shown to reduce the expression of hilA and invasion genes (Lucas et al., 2000). Polissi et al. (1998) identified a pstB mutant in a screen of Streptococcus pneumoniae mutants incapable of surviving in a bacteraemia model. However, to our knowledge, this is the first time that the importance of the pst–phoU operon in virulence has been confirmed using genetic complementation. As in our study, the specific mechanism by which PhoU and other products of the pst–phoU operon contribute to pathogenesis has not been elucidated in these other pathogens.
Although the role of PhoU within the Pho regulon is not fully understood, it seems to act as a negative regulator. Prior work and our results confirm that phoU mutation leads to increased expression of genes normally repressed under conditions, including urine, where Pi is abundant. This inappropriate expression of unnecessary proteins could place an extra burden on a phoU mutant, a burden that does not result in a measurable difference in growth rate, but one that is manifest under the more stringent conditions of in vitro or in vivo competition for growth with a strain that has an intact Pho regulon. It is noteworthy that this defect was more obvious during growth in human urine than in laboratory medium. In an attempt to pinpoint specific metabolic defects that could result in this competitive disadvantage, we compared the phoU mutant with the wild-type strain in both phenotypic (Bochner et al., 2001) and transcript (Snyder et al., 2004) microarrays. However, we could not confirm any specific defect resulting from the phoU mutation that could account for this competitive disadvantage (data not shown). Thus, the precise mechanism by which disregulation of the Pho regulon leads to a defect in colonization of the murine urinary tract remains to be uncovered.
|
ACKNOWLEDGEMENTS |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMETHODSRESULTSDISCUSSIONREFERENCES |
|---|
Bochner, B. R., Gadzinski, P. & Panomitros, E. (2001). Phenotype microarrays for high-throughput phenotypic testing and assay of gene function. Genome Res 11, 1246–1255.
Brinkman, E. & Beckwith, J. (1975). Analysis of the regulation of Escherichia coli alkaline phosphatase synthesis using deletions and 
80 transducing phages. J Mol Biol 96, 307–316.[CrossRef][Medline]
Burall, L. S., Harro, J. M., Li, X., Lockatell, C. V., Himpsl, S. D., Hebel, J. R., Johnson, D. E. & Mobley, H. L. (2004). Proteus mirabilis genes that contribute to pathogenesis of urinary tract infection: identification of 25 signature-tagged mutants attenuated at least 100-fold. Infect Immun 72, 2922–2938.
Connell, H., Agace, W., Klemm, P., Schembri, M., Mårild, S. & Svanborg, C. (1996). Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc Natl Acad Sci U S A 93, 9827–9832.
Culham, D. E., Dalgado, C., Gyles, C. L., Mamelak, D., MacLellan, S. & Wood, J. M. (1998). Osmoregulatory transporter ProP influences colonization of the urinary tract by Escherichia coli. Microbiology 144, 91–102.[Abstract]
Daigle, F., Fairbrother, J. M. & Harel, J. (1995). Identification of a mutation in the pst-phoU operon that reduces pathogenicity of an Escherichia coli strain causing septicemia in pigs. Infect Immun 63, 4924–4927.[Abstract]
Foxman, B., Barlow, R., D'Arcy, H., Gillespie, B. & Sobel, J. D. (2000). Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol 10, 509–515.[CrossRef][Medline]
Guyer, D. M., Radulovic, S., Jones, F. E. & Mobley, H. L. T. (2002). Sat, the secreted autotransporter toxin of uropathogenic Escherichia coli, is a vacuolating cytotoxin for bladder and kidney epithelial cells. Infect Immun 70, 4539–4546.
Johnson, J. R. & Russo, T. A. (2002). Uropathogenic Escherichia coli as agents of diverse non-urinary tract extraintestinal infections. J Infect Dis 186, 859–864.[CrossRef][Medline]
Litwin, M. S., Saigal, C. S., Yano, E. M. & 8 other authors (2005). Urologic diseases in America Project: analytical methods and principal findings. J Urol 173, 933–937.[CrossRef][Medline]
Lucas, R. L., Lostroh, C. P., DiRusso, C. C., Spector, M. P., Wanner, B. L. & Lee, C. A. (2000). Multiple factors independently regulate hilA and invasion gene expression in Salmonella enterica serovar typhimurium. J Bacteriol 182, 1872–1882.
Mobley, H. L. T., Green, D. M., Trifillis, A. L., Johnson, D. E., Chippendale, G. R., Lockatell, C. V., Jones, B. D. & Warren, J. W. (1990). Pyelonephritogenic Escherichia coli and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains. Infect Immun 58, 1281–1289.
Morohoshi, T., Maruo, T., Shirai, Y., Kato, J., Ikeda, T., Takiguchi, N., Ohtake, H. & Kuroda, A. (2002). Accumulation of inorganic polyphosphate in phoU mutants of Escherichia coli and Synechocystis sp. strain PCC6803. Appl Environ Microbiol 68, 4107–4110.
Muda, M., Rao, N. N. & Torriani, A. (1992). Role of PhoU in phosphate transport and alkaline phosphatase regulation. J Bacteriol 174, 8057–8064.
Nagy, G., Dobrindt, U., Schneider, G., Khan, A. S., Hacker, J. & Emody, L. (2002). Loss of regulatory protein RfaH attenuates virulence of uropathogenic Escherichia coli. Infect Immun 70, 4406–4413.
Nakata, A., Amemura, M. & Shinagawa, H. (1984). Regulation of the phosphate regulon in Escherichia coli K-12: regulation of the negative regulatory gene phoU and identification of the gene product. J Bacteriol 159, 979–985.
Polissi, A., Pontiggia, A., Feger, G., Altieri, M., Mottl, H., Ferrari, L. & Simon, D. (1998). Large-scale identification of virulence genes from Streptococcus pneumoniae. Infect Immun 66, 5620–5629.
Redford, P., Roesch, P. L. & Welch, R. A. (2003). degS is necessary for virulence and is among extraintestinal Escherichia coli genes induced in murine peritonitis. Infect Immun 71, 3088–3096.
Rippere-Lampe, K. E., O'Brien, A. D., Conran, R. & Lockman, H. A. (2001). Mutation of the gene encoding cytotoxic necrotizing factor type 1 (cnf1) attenuates the virulence of uropathogenic Escherichia coli. Infect Immun 69, 3954–3964.
Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989). Molecular Cloning: a Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
Snyder, J. A., Haugen, B. J., Buckles, E. L., Lockatell, C. V., Johnson, D. E., Donnenberg, M. S., Welch, R. A. & Mobley, H. L. (2004). Transcriptome of uropathogenic Escherichia coli during urinary tract infection. Infect Immun 72, 6373–6381.
Steed, P. M. & Wanner, B. L. (1993). Use of the rep technique for allele replacement to construct mutants with deletions of the pstSCAB-phoU operon: evidence of a new role for the PhoU protein in the phosphate regulon. J Bacteriol 175, 6797–6809.
Surin, B. P., Rosenberg, H. & Cox, G. B. (1985). Phosphate-specific transport system of Escherichia coli: nucleotide sequence and gene-polypeptide relationships. J Bacteriol 161, 189–198.
Torres, A. G., Redford, P., Welch, R. A. & Payne, S. M. (2001). TonB-dependent systems of uropathogenic Escherichia coli: aerobactin and heme transport and TonB are required for virulence in the mouse. Infect Immun 69, 6179–6185.
Wang, R. F. & Kushner, S. R. (1991). Construction of versatile low-copy-number vectors for cloning, sequencing and gene expression in Escherichia coli. Gene 100, 195–199.[CrossRef][Medline]
Wanner, B. L. (1996). Phosphorus assimilation and control of the phosphate regulon. In Escherichia coli and Salmonella: Cellular and Molecular Biology, pp. 1357–1381. Edited by F. C. Neidhardt and others. Washington, DC: American Society for Microbiology.
Welch, R. A., Burland, V., Plunkett, G., III & 16 other authors (2002). Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli. Proc Natl Acad Sci U S A 99, 17020–17024.
Received 20 June 2005;
revised 27 September 2005;
accepted 11 October 2005.
This article has been cited by other articles:
|
|
 |
|
  G. M. Ferreira and B. Spira The pst operon of enteropathogenic Escherichia coli enhances bacterial adherence to epithelial cells Microbiology, July 1, 2008; 154(7): 2025 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Bansal, D. Englert, J. Lee, M. Hegde, T. K. Wood, and A. Jayaraman Differential Effects of Epinephrine, Norepinephrine, and Indole on Escherichia coli O157:H7 Chemotaxis, Colonization, and Gene Expression Infect. Immun., September 1, 2007; 75(9): 4597 - 4607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Haugen, S. Pellett, P. Redford, H. L. Hamilton, P. L. Roesch, and R. A. Welch In Vivo Gene Expression Analysis Identifies Genes Required for Enhanced Colonization of the Mouse Urinary Tract by Uropathogenic Escherichia coli Strain CFT073 dsdA Infect. Immun., January 1, 2007; 75(1): 278 - 289. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
, Wild-type E. coli strain CFT073; 
, phoU mutant strain 3A-E4. In (a) and (c), both strains contained the control plasmid pWKS30; in (b) and (d), the wild-type contained pWKS30 and the mutant contained the complementing plasmid pXLW31. Data are the means±SEM of three independent experiments (some of the error bars are smaller than the symbols). Note that the scale on the x-axis is not linear.